Consumption of 4D Dietary Supplement on Perceptual-Cognitive and Visual-Motor Performance

October 7, 2021 updated by: University of Central Florida

Acute Consumption of 4D Dietary Supplement vs. Placebo: Effects on Perceptual-Cognitive and Visual-Motor Performance

The purpose of this investigation is to determine if supplementation with the 4D dietary supplement impacts perceptual-cognitive and visual-motor skills in healthy individuals.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Detailed Description

Multi-ingredient supplements (MIS) have been reported to positively impact various aspects of performance. While caffeine alone has been shown to improve aerobic performance, resistance training (such as bench press), reaction time and sprint performance, it has also been suggested that it lacks the ability to improve cognition. Therefore, the purpose of this investigation is to examine the effects of a caffeine containing MIS on measures of cognition and reaction time, with the intent of providing additional benefits to athletic performance.

This study will utilize a randomized, double-blind, placebo-controlled design. Following two familiarization trials, participants will complete two testing visits. During these visits, they will complete baseline assessments, consume either the 4D dietary supplement or a taste matched placebo, and rest for 45 minutes. Reaction time, cognition assessments (visual tracking speed), and reactive agility performance will be assessed following the rest period.

Study Type

Interventional

Enrollment (Actual)

24

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • United States
    • Florida
      • Orlando, Florida, United States, 32816
        • University of Central Florida

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

14 years to 36 years (Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Male or female between the ages of 18-40 years old
  • Determined to be healthy by the MHQ and PAR-Q+

Exclusion Criteria:

  • Any response of "yes" on the PAR-Q+
  • Daily caffeine consumption greater than 200 mg

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Other
  • Allocation: Randomized
  • Interventional Model: Crossover Assignment
  • Masking: Double

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: 4D dietary supplement
Multi-ingredient supplement containing a proprietary blend with 150mg of caffeine, and other ingredients including vitamins, electrolytes, and BCAA blend (150mg).
Dietary supplement: 4D
multi-ingredient supplement mixed with 24 ounces of water
Placebo Comparator: placebo
flavored water (raspberry lemonade Crystal Light®)
Dietary supplement: placebo
taste-matched placebo mixed with 24 ounces of water
Other Names:
  • Crystal Light®

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change in reactive agility time
Time Frame: post supplement ingestion on both testing days (Day 3 and Day 4)
Determined via Y-Reactive Agility test using the Witty Wireless Timing Gate system
post supplement ingestion on both testing days (Day 3 and Day 4)
Change in reaction time in response to supplement/placebo consumption
Time Frame: pre and post supplement ingestion on both testing days (Day 3 and Day 4)
Determined via Dynavision D2, Mode A
pre and post supplement ingestion on both testing days (Day 3 and Day 4)
Change in visual tracking speed in response to supplement/placebo consumption
Time Frame: pre and post supplement ingestion on both testing days (Day 3 and Day 4)
Determined via multiple object tracking test on the Neurotracker
pre and post supplement ingestion on both testing days (Day 3 and Day 4)

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

University of Central Florida

Collaborators

4D, LLC

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

July 26, 2021

Primary Completion (Actual)

October 4, 2021

Study Completion (Actual)

October 4, 2021

Study Registration Dates

First Submitted

July 14, 2021

First Submitted That Met QC Criteria

July 23, 2021

First Posted (Actual)

August 4, 2021

Study Record Updates

Last Update Posted (Actual)

October 8, 2021

Last Update Submitted That Met QC Criteria

October 7, 2021

Last Verified

October 1, 2021

More Information

Terms related to this study

Keywords

Other Study ID Numbers

  • STUDY00003029

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

No

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe